Moderna, Inc. (MRNA)

Moderna Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	6,848	19,263	18,471	803	60
Revenue Growth (YoY)	-64.45%	4.29%	2200.25%	1238.33%	-55.58%
Cost of Revenue	4,693	5,416	2,617	8	0
Gross Profit	2,155	13,847	15,854	795	60
Selling, General & Admin	1,549	1,132	567	188	110
Research & Development	4,845	3,295	1,991	1,370	496
Operating Expenses	6,394	4,427	2,558	1,558	606
Operating Income	-4,239	9,420	13,296	-763	-546
Other Expense / Income	-297	-155	11	-19	-31
Pretax Income	-3,942	9,575	13,285	-744	-515
Income Tax	772	1,213	1,083	3	-1
Net Income	-4,714	8,362	12,202	-747	-514
Net Income Growth	-	-31.47%	-	-	-
Shares Outstanding (Basic)	382	394	403	381	331
Shares Outstanding (Diluted)	382	416	431	381	331
Shares Change	-8.17%	-3.48%	13.12%	15.11%	308.07%
EPS (Basic)	-12.33	21.26	30.31	-1.96	-1.55
EPS (Diluted)	-12.33	20.12	28.29	-1.96	-1.55
EPS Growth	-	-28.88%	-	-	-
Free Cash Flow	-3,825	4,581	13,336	1,959	-491
Free Cash Flow Per Share	-10.01	11.63	33.09	5.14	-1.48
Gross Margin	31.47%	71.88%	85.83%	99.00%	100.00%
Operating Margin	-61.90%	48.90%	71.98%	-95.02%	-910.00%
Profit Margin	-68.84%	43.41%	66.06%	-93.03%	-856.67%
Free Cash Flow Margin	-55.86%	23.78%	72.20%	243.96%	-818.33%
Effective Tax Rate	-	12.67%	8.15%	-	-
EBITDA	-3,321	9,923	13,517	-651	-484
EBITDA Margin	-48.50%	51.51%	73.18%	-81.07%	-806.67%
Depreciation & Amortization	621	348	232	93	31
EBIT	-3,942	9,575	13,285	-744	-515
EBIT Margin	-57.56%	49.71%	71.92%	-92.65%	-858.33%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).